Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines committee ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.